156 related articles for article (PubMed ID: 36637703)
1. Population Pharmacokinetics, Pharmacogenomics, and Adverse Events of Osimertinib and its Two Active Metabolites, AZ5104 and AZ7550, in Japanese Patients with Advanced Non-small Cell Lung Cancer: a Prospective Observational Study.
Ishikawa E; Yokoyama Y; Chishima H; Kasai H; Kuniyoshi O; Kimura M; Hakamata J; Nakada H; Suehiro N; Nakaya N; Nakajima H; Ikemura S; Kawada I; Yasuda H; Terai H; Jibiki A; Kawazoe H; Soejima K; Muramatsu H; Suzuki S; Nakamura T
Invest New Drugs; 2023 Feb; 41(1):122-133. PubMed ID: 36637703
[TBL] [Abstract][Full Text] [Related]
2. Association of
Tanda M; Yamamoto K; Hori T; Nishiguchi H; Yagi M; Shimizu M; Konishi T; Ozaki T; Yoshioka N; Tachihara M; Ito T; Ikushima S; Omura T; Yano I
Anticancer Res; 2023 Apr; 43(4):1775-1783. PubMed ID: 36974789
[TBL] [Abstract][Full Text] [Related]
3. A Validated Assay to Quantify Osimertinib and Its Metabolites, AZ5104 and AZ7550, from Microsampled Dried Blood Spots and Plasma.
Venkatesh B; Yuile A; McKay MJ; Narayanan S; Wheeler H; Itchins M; Pavlakis N; Clarke SJ; Molloy MP
Ther Drug Monit; 2024 Jun; 46(3):332-343. PubMed ID: 38263583
[TBL] [Abstract][Full Text] [Related]
4. Relationship Between Osimertinib Concentration and Clinical Response in Japanese Patients With Non-small Cell Lung Cancer.
Yamazaki M; Komizo N; Iihara H; Hirose C; Yanase K; Yamada Y; Endo J; Yamashita S; Ohno Y; Todoroki K; Suzuki A; Hayashi H
Anticancer Res; 2023 Feb; 43(2):725-732. PubMed ID: 36697059
[TBL] [Abstract][Full Text] [Related]
5. Metabolic Disposition of Osimertinib in Rats, Dogs, and Humans: Insights into a Drug Designed to Bind Covalently to a Cysteine Residue of Epidermal Growth Factor Receptor.
Dickinson PA; Cantarini MV; Collier J; Frewer P; Martin S; Pickup K; Ballard P
Drug Metab Dispos; 2016 Aug; 44(8):1201-12. PubMed ID: 27226351
[TBL] [Abstract][Full Text] [Related]
6. Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis.
Hirashima T; Satouchi M; Hida T; Nishio M; Kato T; Sakai H; Imamura F; Kiura K; Okamoto I; Kasahara K; Uchida H; Vowler SL; Mitsudomi T
Cancer Sci; 2019 Sep; 110(9):2884-2893. PubMed ID: 31265163
[TBL] [Abstract][Full Text] [Related]
7. Bioanalysis of EGFRm inhibitor osimertinib, and its glutathione cycle- and desmethyl metabolites by liquid chromatography-tandem mass spectrometry.
Rood JJM; van Haren MJ; Beijnen JH; Sparidans RW
J Pharm Biomed Anal; 2020 Jan; 177():112871. PubMed ID: 31539712
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of a new liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of afatinib, dacomitinib, osimertinib, and the active metabolites of osimertinib in human serum.
Ishikawa E; Yokoyama Y; Chishima H; Kuniyoshi O; Sato I; Nakaya N; Nakajima H; Kimura M; Hakamata J; Suehiro N; Nakada H; Ikemura S; Jibiki A; Kawazoe H; Muramatsu H; Suzuki S; Nakamura T
J Chromatogr B Analyt Technol Biomed Life Sci; 2022 May; 1199():123245. PubMed ID: 35436724
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic boosting of osimertinib with cobicistat in patients with non-small cell lung cancer: The OSIBOOST trial.
van Veelen A; Gulikers J; Hendriks LEL; Dursun S; Ippel J; Smit EF; Dingemans AC; van Geel R; Croes S
Lung Cancer; 2022 Sep; 171():97-102. PubMed ID: 35933915
[TBL] [Abstract][Full Text] [Related]
10. Modulation of Fexofenadine Pharmacokinetics by Osimertinib in Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer.
Calvo E; Lee JS; Kim SW; Moreno V; deCastro Carpeno J; Weilert D; Laus G; Mann H; Vishwanathan K
J Clin Pharmacol; 2019 Aug; 59(8):1099-1109. PubMed ID: 30875094
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety Data of Osimertinib in Elderly Patients with NSCLC Who Harbor the
Furuta H; Uemura T; Yoshida T; Kobara M; Yamaguchi T; Watanabe N; Shimizu J; Horio Y; Kuroda H; Sakao Y; Yatabe Y; Hida T
Anticancer Res; 2018 Sep; 38(9):5231-5237. PubMed ID: 30194172
[TBL] [Abstract][Full Text] [Related]
12. Brain accumulation of osimertinib and its active metabolite AZ5104 is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein).
van Hoppe S; Jamalpoor A; Rood JJM; Wagenaar E; Sparidans RW; Beijnen JH; Schinkel AH
Pharmacol Res; 2019 Aug; 146():104297. PubMed ID: 31175939
[TBL] [Abstract][Full Text] [Related]
13. Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial.
Akamatsu H; Katakami N; Okamoto I; Kato T; Kim YH; Imamura F; Shinkai M; Hodge RA; Uchida H; Hida T
Cancer Sci; 2018 Jun; 109(6):1930-1938. PubMed ID: 29697876
[TBL] [Abstract][Full Text] [Related]
14. Absolute Bioavailability of Osimertinib in Healthy Adults.
Vishwanathan K; So K; Thomas K; Bramley A; English S; Collier J
Clin Pharmacol Drug Dev; 2019 Feb; 8(2):198-207. PubMed ID: 29683562
[TBL] [Abstract][Full Text] [Related]
15. EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer.
Fang W; Huang Y; Hong S; Zhang Z; Wang M; Gan J; Wang W; Guo H; Wang K; Zhang L
BMC Cancer; 2019 Jun; 19(1):595. PubMed ID: 31208370
[TBL] [Abstract][Full Text] [Related]
16. Real-world data on treatment outcomes in
Dal Maso A; Lorenzi M; Ferro A; Pilotto S; Cecere F; Follador A; Polo V; Del Conte A; Sartori G; Giavarra M; Scattolin D; Indraccolo S; Frega S; De Maglio G; Menis J; Bonanno L; Calabrese F; Guarneri V; Conte P; Pasello G
Future Oncol; 2021 Jul; 17(19):2513-2527. PubMed ID: 33988036
[TBL] [Abstract][Full Text] [Related]
17. First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: A prospective observational study.
Igawa S; Fukui T; Kasajima M; Ono T; Ozawa T; Kakegawa M; Kusuhara S; Sato T; Nakahara Y; Hisashi M; Sasaki J; Naoki K
Invest New Drugs; 2022 Apr; 40(2):430-437. PubMed ID: 34807331
[TBL] [Abstract][Full Text] [Related]
18. Effects of pharmacokinetics-related genetic polymorphisms on the side effect profile of afatinib in patients with non-small cell lung cancer.
Hayashi H; Iihara H; Hirose C; Fukuda Y; Kitahora M; Kaito D; Yanase K; Endo J; Ohno Y; Suzuki A; Sugiyama T
Lung Cancer; 2019 Aug; 134():1-6. PubMed ID: 31319966
[TBL] [Abstract][Full Text] [Related]
19. Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions.
Floc'h N; Martin MJ; Riess JW; Orme JP; Staniszewska AD; Ménard L; Cuomo ME; O'Neill DJ; Ward RA; Finlay MRV; McKerrecher D; Cheng M; Vang DP; Burich RA; Keck JG; Gandara DR; Mack PC; Cross DAE
Mol Cancer Ther; 2018 May; 17(5):885-896. PubMed ID: 29483211
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic profiles of significant adverse events with crizotinib in Japanese patients with ABCB1 polymorphism.
Fujiwara Y; Hamada A; Mizugaki H; Aikawa H; Hata T; Horinouchi H; Kanda S; Goto Y; Itahashi K; Nokihara H; Yamamoto N; Ohe Y
Cancer Sci; 2016 Aug; 107(8):1117-23. PubMed ID: 27270784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
